Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности применения торасемида в клинической практике
Современные возможности применения торасемида в клинической практике
Батищева Г.А., Мубаракшина О.А., Сомова М.Н., Евстигнеева А.С. Современные возможности применения торасемида в клинической практике. Consilium Medicum. 2017; 19 (5): 64–67.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представитель нового поколения петлевых диуретиков торасемид демонстрирует высокую эффективность и высокий профиль безопасности при лечении пациентов с сердечной недостаточностью и артериальной гипертензией. Препарат не только оказывает влияние на симптомы, но и вмешивается в патогенез сердечно-сосудистого континуума, улучшает качество жизни и прогноз кардиологических пациентов. Подтвержденная в клинических исследованиях эффективность и хорошая переносимость позволяют широко рекомендовать отечественный препарат торасемида Тригрим® в терапии пациентов с артериальной гипертензией, отечным синдромом, в том числе на фоне хронической сердечной недостаточности.
Ключевые слова: диуретики, хроническая сердечная недостаточность, торасемид, Тригрим®.
Key words: diuretics, chronic heart failure, torasemide, Trigrim®.
Ключевые слова: диуретики, хроническая сердечная недостаточность, торасемид, Тригрим®.
________________________________________________
Key words: diuretics, chronic heart failure, torasemide, Trigrim®.
Полный текст
Список литературы
1. Withering W. An acconnt ot the fox-glove and some of its medical uses; with practical remarks of dropsy and other diseases. Birmingham, 1885.
2. Hutchen DE, Mehta D, Romano A. Diuretic action of furosemide. Arch Intern Med 1965; 115: 542.
3. Saxl P, Heiling R. Uber die diuretiche Wircung von Novasurol und anderen Quecksiberinjektionen. Wein Klin Wochenschr 1920; 33: 943.
4. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
5. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА, 2005. / Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. M.: MIA, 2005. [in Russian]
6. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диyретическая терапия Эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ – ХСН). Сердечная недостаточность. 2011; 12 (3): 3–10. / Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia Effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'' – KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
7. Преображенский Д.В., Некрасова Н.И., Талызина И.В., Патарая С.А. Торасемид – петлевой диуретик нового поколения: особенности фармакологии и клиническая эффективность при сердечной недостаточности. Сердечная недостаточность. 2010; 11 (5): 294–300. / Preobrazhenskii D.V., Nekrasova N.I., Talyzina I.V., Pataraia S.A. Torasemid – petlevoi diuretik novogo pokoleniia: osobennosti farmakologii i klinicheskaia effektivnost' pri serdechnoi nedostatochnosti. Serdechnaia nedostatochnost'. 2010; 11 (5): 294–300. [in Russian]
8. Rosón M, Cavallero S, Della Penna S et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 2006; 70 (8): 1439–46.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–10.
10. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
11. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (Suppl. 5): 384–90.
12. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
13. Cosin J, Diez J. and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (Suppl. 4): 507–13.
14. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (Suppl. 7): 513–20.
15. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furo-semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (Suppl. 37): 1467–75.
16. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (Suppl. 6): 793–801.
17. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
18. Han LN, Guo SL, Lin XM et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res 2014; 13 (3): 7262–74.
19. Knauf H, Mutschler E, Velazquez H, Giebisch G. Tora semide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
20. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar-teriosa: Studio con trolla to in doppla cecita. Bas Razion Terapia 1990; 20: 407–10.
21. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 169–81.
22. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25-50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
23. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 211–20.
24. Теблоев К.И., Евдокимова А.Г., Ложкина М.В., Евдокимов В.В. Современные возможности оптимизации лечения больных АГ и ХСН при применении торасемида. РМЖ. 2013; 27: 1388. / Tebloev K.I., Evdokimova A.G., Lozhkina M.V., Evdokimov V.V. Sovremennye vozmozhnosti optimizatsii lecheniia bol'nykh AG i KhSN pri primenenii torasemida. RMZh. 2013; 27: 1388. [in Russian]
25. Свиряев Ю.В., Звартау Н.Э., Коростовцева Л.С. и др. Сравнительная оценка эффективности и безопасности Тригрима и Арифона Ретард у больных с арТериальной гипертонией в слепом рандомизированном исследовании в параллельных группах (исследование СТАРТ). Сердце. 2014; 13 (6): 389–95. / Sviriaev Iu.V., Zvartau N.E., Korostovtseva L.S. i dr. Sravnitel'naia otsenka effektivnosti i bezopasnosti Trigrima i Arifona Retard u bol'nykh s arTerial'noi gipertoniei v slepom randomizirovannom issledovanii v parallel'nykh gruppakh (issledovanie START). Serdtse. 2014; 13 (6): 389–95. [in Russian]
2. Hutchen DE, Mehta D, Romano A. Diuretic action of furosemide. Arch Intern Med 1965; 115: 542.
3. Saxl P, Heiling R. Uber die diuretiche Wircung von Novasurol und anderen Quecksiberinjektionen. Wein Klin Wochenschr 1920; 33: 943.
4. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
5. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. M.: MIA, 2005. [in Russian]
6. Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia Effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'' – KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
7. Preobrazhenskii D.V., Nekrasova N.I., Talyzina I.V., Pataraia S.A. Torasemid – petlevoi diuretik novogo pokoleniia: osobennosti farmakologii i klinicheskaia effektivnost' pri serdechnoi nedostatochnosti. Serdechnaia nedostatochnost'. 2010; 11 (5): 294–300. [in Russian]
8. Rosón M, Cavallero S, Della Penna S et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 2006; 70 (8): 1439–46.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–10.
10. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
11. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (Suppl. 5): 384–90.
12. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
13. Cosin J, Diez J. and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (Suppl. 4): 507–13.
14. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (Suppl. 7): 513–20.
15. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furo-semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (Suppl. 37): 1467–75.
16. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (Suppl. 6): 793–801.
17. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
18. Han LN, Guo SL, Lin XM et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res 2014; 13 (3): 7262–74.
19. Knauf H, Mutschler E, Velazquez H, Giebisch G. Tora semide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
20. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar-teriosa: Studio con trolla to in doppla cecita. Bas Razion Terapia 1990; 20: 407–10.
21. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 169–81.
22. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25-50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
23. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 211–20.
24. Tebloev K.I., Evdokimova A.G., Lozhkina M.V., Evdokimov V.V. Sovremennye vozmozhnosti optimizatsii lecheniia bol'nykh AG i KhSN pri primenenii torasemida. RMZh. 2013; 27: 1388. [in Russian]
25. Sviriaev Iu.V., Zvartau N.E., Korostovtseva L.S. i dr. Sravnitel'naia otsenka effektivnosti i bezopasnosti Trigrima i Arifona Retard u bol'nykh s arTerial'noi gipertoniei v slepom randomizirovannom issledovanii v parallel'nykh gruppakh (issledovanie START). Serdtse. 2014; 13 (6): 389–95. [in Russian]
2. Hutchen DE, Mehta D, Romano A. Diuretic action of furosemide. Arch Intern Med 1965; 115: 542.
3. Saxl P, Heiling R. Uber die diuretiche Wircung von Novasurol und anderen Quecksiberinjektionen. Wein Klin Wochenschr 1920; 33: 943.
4. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
5. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА, 2005. / Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. M.: MIA, 2005. [in Russian]
6. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диyретическая терапия Эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ – ХСН). Сердечная недостаточность. 2011; 12 (3): 3–10. / Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia Effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'' – KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
7. Преображенский Д.В., Некрасова Н.И., Талызина И.В., Патарая С.А. Торасемид – петлевой диуретик нового поколения: особенности фармакологии и клиническая эффективность при сердечной недостаточности. Сердечная недостаточность. 2010; 11 (5): 294–300. / Preobrazhenskii D.V., Nekrasova N.I., Talyzina I.V., Pataraia S.A. Torasemid – petlevoi diuretik novogo pokoleniia: osobennosti farmakologii i klinicheskaia effektivnost' pri serdechnoi nedostatochnosti. Serdechnaia nedostatochnost'. 2010; 11 (5): 294–300. [in Russian]
8. Rosón M, Cavallero S, Della Penna S et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 2006; 70 (8): 1439–46.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–10.
10. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
11. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (Suppl. 5): 384–90.
12. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
13. Cosin J, Diez J. and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (Suppl. 4): 507–13.
14. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (Suppl. 7): 513–20.
15. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furo-semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (Suppl. 37): 1467–75.
16. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (Suppl. 6): 793–801.
17. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
18. Han LN, Guo SL, Lin XM et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res 2014; 13 (3): 7262–74.
19. Knauf H, Mutschler E, Velazquez H, Giebisch G. Tora semide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
20. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar-teriosa: Studio con trolla to in doppla cecita. Bas Razion Terapia 1990; 20: 407–10.
21. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 169–81.
22. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25-50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
23. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 211–20.
24. Теблоев К.И., Евдокимова А.Г., Ложкина М.В., Евдокимов В.В. Современные возможности оптимизации лечения больных АГ и ХСН при применении торасемида. РМЖ. 2013; 27: 1388. / Tebloev K.I., Evdokimova A.G., Lozhkina M.V., Evdokimov V.V. Sovremennye vozmozhnosti optimizatsii lecheniia bol'nykh AG i KhSN pri primenenii torasemida. RMZh. 2013; 27: 1388. [in Russian]
25. Свиряев Ю.В., Звартау Н.Э., Коростовцева Л.С. и др. Сравнительная оценка эффективности и безопасности Тригрима и Арифона Ретард у больных с арТериальной гипертонией в слепом рандомизированном исследовании в параллельных группах (исследование СТАРТ). Сердце. 2014; 13 (6): 389–95. / Sviriaev Iu.V., Zvartau N.E., Korostovtseva L.S. i dr. Sravnitel'naia otsenka effektivnosti i bezopasnosti Trigrima i Arifona Retard u bol'nykh s arTerial'noi gipertoniei v slepom randomizirovannom issledovanii v parallel'nykh gruppakh (issledovanie START). Serdtse. 2014; 13 (6): 389–95. [in Russian]
________________________________________________
2. Hutchen DE, Mehta D, Romano A. Diuretic action of furosemide. Arch Intern Med 1965; 115: 542.
3. Saxl P, Heiling R. Uber die diuretiche Wircung von Novasurol und anderen Quecksiberinjektionen. Wein Klin Wochenschr 1920; 33: 943.
4. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
5. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. M.: MIA, 2005. [in Russian]
6. Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia Effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'' – KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
7. Preobrazhenskii D.V., Nekrasova N.I., Talyzina I.V., Pataraia S.A. Torasemid – petlevoi diuretik novogo pokoleniia: osobennosti farmakologii i klinicheskaia effektivnost' pri serdechnoi nedostatochnosti. Serdechnaia nedostatochnost'. 2010; 11 (5): 294–300. [in Russian]
8. Rosón M, Cavallero S, Della Penna S et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 2006; 70 (8): 1439–46.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–10.
10. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
11. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (Suppl. 5): 384–90.
12. Goodfriend TL, Ball DL, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45–50.
13. Cosin J, Diez J. and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (Suppl. 4): 507–13.
14. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (Suppl. 7): 513–20.
15. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furo-semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (Suppl. 37): 1467–75.
16. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (Suppl. 6): 793–801.
17. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
18. Han LN, Guo SL, Lin XM et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res 2014; 13 (3): 7262–74.
19. Knauf H, Mutschler E, Velazquez H, Giebisch G. Tora semide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
20. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar-teriosa: Studio con trolla to in doppla cecita. Bas Razion Terapia 1990; 20: 407–10.
21. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 169–81.
22. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25-50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
23. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 211–20.
24. Tebloev K.I., Evdokimova A.G., Lozhkina M.V., Evdokimov V.V. Sovremennye vozmozhnosti optimizatsii lecheniia bol'nykh AG i KhSN pri primenenii torasemida. RMZh. 2013; 27: 1388. [in Russian]
25. Sviriaev Iu.V., Zvartau N.E., Korostovtseva L.S. i dr. Sravnitel'naia otsenka effektivnosti i bezopasnosti Trigrima i Arifona Retard u bol'nykh s arTerial'noi gipertoniei v slepom randomizirovannom issledovanii v parallel'nykh gruppakh (issledovanie START). Serdtse. 2014; 13 (6): 389–95. [in Russian]
Авторы
Г.А.Батищева, О.А.Мубаракшина*, М.Н.Сомова, А.С.Евстигнеева
ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н.Бурденко» Минздрава России. 394036, Россия, Воронеж, ул. Студенческая, д. 10
*mubarakshina@mail.ru
Voronezh State Medical University of the Ministry of Health of the Russian Federation. 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10
*mubarakshina@mail.ru
ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н.Бурденко» Минздрава России. 394036, Россия, Воронеж, ул. Студенческая, д. 10
*mubarakshina@mail.ru
________________________________________________
Voronezh State Medical University of the Ministry of Health of the Russian Federation. 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10
*mubarakshina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.